Finance
Exclusive-AstraZeneca pauses $270 million investment in Britain
Published by Global Banking and Finance Review
Posted on September 12, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on September 12, 2025
By Alistair Smout and Maggie Fick
LONDON (Reuters) - Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.
The decision on the investment, which had been set to create 1,000 jobs, means none of AstraZeneca's planned new funding - originally announced in March 2024 - is currently proceeding.
In January, the company scrapped plans to invest 450 million pounds in its vaccine manufacturing plant in northern England, citing a cut in British government support.
U.S. drugmaker Merck & Co this week blamed the UK's challenging business environment as it abandoned a new research centre in London.
Asked about speculation over its pharmaceutical investments following the Merck announcement, a spokesperson for AstraZeneca, which has the biggest market capitalisation on the FTSE 100, confirmed it would pause its investment plans in Cambridge, where it has one of Britain's leading life sciences hubs.
"We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused. We have no further comment to make," an AstraZeneca spokesperson said.
The news, which will come as a blow to Prime Minister Keir Starmer's government and its efforts to draw investment into the UK's stagnant economy, comes just days before U.S. President Donald Trump arrives in Britain for a state visit.
AstraZeneca in July said it would spend $50 billion to expand manufacturing and research capabilities in the United States by 2030 - one of many announcements by pharmaceutical companies reacting to Trump's tariff policy.
Trump has criticised Britain and Europe for not paying high enough prices for drugs, and several pharmaceutical firms have criticised Britain for what they say is long-term undervaluation of medicines and innovation.
After AstraZeneca dropped its vaccine plant investment plan, Chief Executive Pascal Soriot urged Britain to improve the environment for businesses in order to drive investment.
($1 = 0.7373 pounds)
(Reporting by Alistair Smout and Maggie Fick; Editing by Kirsten Donovan)